<DOC>
	<DOCNO>NCT02133131</DOCNO>
	<brief_summary>This study grazoprevir ( MK-5172 ) + elbasvir ( MK-8742 ) sofosbuvir ( SOF ) treatment-naive participant chronic hepatitis C ( HCV ) genotype ( GT ) 1 GT3 . The objective determine proportion participant achieve sustain virologic response 12 week end study treatment ( SVR12 ) .</brief_summary>
	<brief_title>Efficacy Safety Grazoprevir ( MK-5172 ) , Elbasvir ( MK-8742 ) , Sofosbuvir Chronic Infection With Hepatitis C Virus Genotypes 1 3 ( MK-5172-074 )</brief_title>
	<detailed_description>The study open-label , single-center , multiple-arm investigation fixed-dose combination [ FDC ] grazoprevir 100mg + elbasvir 50mg , SOF 400mg , treatment-naive participant chronic HCV GT1 GT3 . The impact study treatment regimens vary duration SVR12 ( undetectable HCV ribonucleic acid [ RNA ] 12 week end study treatment ) cirrhotic ( C ) participants non-cirrhotic ( NC ) participant determine ( Part A ) . Any HCV GT1 participant study Arms 1-4 Part A experience virologic relapse offer retreatment consist 12 additional week treatment MK-5172/MK-8742 + SOF + ribavirin 24 week follow-up Part B .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCV RNA ≥10,000 IU/mL peripheral blood time screen document chronic HCV GT1 GT3 infection either negative positive history liver cirrhosis base liver biopsy , Fibroscan , FibroSure ® ( Fibrotest® ) treatment naïve antiHCV treatment evidence decompensated liver disease coinfected hepatitis B virus ( e.g . hepatitis B surface antigen positive ) human immunodeficiency virus history malignancy ≤5 year prior sign inform consent , evaluation active suspected malignancy cirrhosis liver image within 6 month Day 1 show evidence hepatocellular carcinoma ( HCC ) evaluation HCC clinicallyrelevant drug alcohol abuse within 12 month screen follow condition : organ transplant cornea hair , poor venous access precludes routine peripheral blood sampling , history gastric surgery malabsorption disorder , medical condition requiring , likely require , chronic systemic administration corticosteroid course trial history chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>